Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study
Cesare Berra, Roberto Manfrini, Francesco Bifari, Elisa Cipponeri, Renata Ghelardi, Lucia Centofanti, Umberto Mortola, Elena Lunati, Loredana Bucciarelli, Vincenzo Cimino, Franco Folli
Abstract
; p<0.0001). Efficacy of Dulaglutide was not affected by different CVD risk categories, age and T2DM duration. This real world study provides evidence for significant reductions in HbA1c level, body mass index and body weight in obese type 2 diabetic patients who received add-on treatment with the weekly GLP-1RA, Dulaglutide.
Topics & Concepts
DulaglutideGlycemicMedicineType 2 diabetesInternal medicineDiabetes mellitusEndocrinologyInsulinExenatideDiabetes Treatment and ManagementDiabetes Management and ResearchDiet and metabolism studies